OSUR OraSure Technologies, Inc.: Total Company Value-to-Revenue Ratio

Public company logo of OraSure Technologies, Inc. (OSUR)

OraSure Technologies (OSUR) is transforming its model toward molecular diagnostics and clinical rapid tests. Effective pharmacy distribution and supply chain protection support high margins. The company's valuation based on the EV/Sales multiple reflects market expectations, where 1014.37 determines this parameter level. Production precision is ensured by robotic assembly lines that minimize manual labor.

OSUR OraSure Corp Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for OraSure Technologies Inc (OSUR)

- current quotes and average value forecast:
Fundamental valuation:OraSure Technologies (OSUR)
Core merchandise of OraSure Technologies, Inc.

This metric compares the combined value of assets and debt against annual sales volume, excluding the impact of leverage. It measures the market premium per unit of revenue, signaling a business overvaluation during sharp spikes in demand. Patent protection and FDA approvals for OraSure Technologies (OSUR) create a sustainable barrier that justifies the high cost of operational resilience. By analyzing the business value-to-revenue dynamics, an investor can identify trend reversal points, allowing for the timely determination of the optimal moment to open positions.

Competitor analysis for OraSure Technologies

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|Company Value to Revenue XGN (Exagen Diagnostics)|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue